Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8844622 | Experimental Parasitology | 2018 | 19 Pages |
Abstract
We constructed a new plasmid pIRESneo/ROP18/PLP1 that was injected intramuscularly into Kunming mice to evaluate its immune efficacy. The immunized mice exhibited significantly increased serum IgG2a levels, lymphocyte counts and Th1-type cytokine (IL-2, IL-12 and IFN-γ) levels. Moreover, the immunized mice exhibited longer survival times (44.7 ± 2.1 days for ROP18/PLP1 and 47.2 ± 2.9 days for ROP18/PLP1 + IL-18) and lower brain cyst burden (68.9% for ROP18/PLP1 and 72.4% for ROP18/PLP1 + IL-18) than control mice after T. gondii challenge. Our results demonstrate that the multiple-gene DNA vaccine including both ROP18 and PLP1 elicits greater protection against T. gondii challenge and stronger immunogenicity than single-gene vaccines.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Parasitology
Authors
Yajun Chen, Miao Yu, J.A. Hemandez, Jiexi Li, Zi-Guo Yuan, Haikuo Yan,